# Clinical Efficacy and Safety of CD47 Monoclonal Antibody Combined With Azacitidine in the Treatment of Recurrent AML After Transplantation

> **NCT05266274** · NA · UNKNOWN · sponsor: **The First Affiliated Hospital of Soochow University** · enrollment: 69 (estimated)

## Conditions studied

- Patients With Recurrent Acute Myelogenous Leukemia After Transplantation

## Interventions

- **DRUG:** CD47 monoclonal antibody

## Key facts

- **NCT ID:** NCT05266274
- **Lead sponsor:** The First Affiliated Hospital of Soochow University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-12-14
- **Primary completion:** 2023-06-30
- **Final completion:** 2023-12-31
- **Target enrollment:** 69 (ESTIMATED)
- **Last updated:** 2022-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05266274

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05266274, "Clinical Efficacy and Safety of CD47 Monoclonal Antibody Combined With Azacitidine in the Treatment of Recurrent AML After Transplantation". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT05266274. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*